TY - JOUR
T1 - A Month-by-Month Long-Term Study on Carbamazepine
T2 - Clinical, EEG and Pharmacological Evaluation
AU - Monaco, F.
AU - Riccio, A.
AU - Fantini, M.
AU - Baruzzi, A.
AU - Morselli, P. L.
PY - 1979
Y1 - 1979
N2 - Carbamazepine plasma levels were monitored for a twelve-month period in twenty epileptic patients. Seizure frequency decreased remarkably on inclusion of the drug in the therapy and attainment of plasma levels of 7-9 μg/ml. A faster breakdown rate in children was confirmed, while carbamazepine-10, 11-epoxide was present for carbamazepine levels above 4-5 μg/ml. EEG tracings did not show substantial modifications; this variable was thus considered to be of little value in assessing the clinical picture. Side-effects were minimal. Carbamazepine is increasingly becoming the drug of first choice in the management of both generalized and partial epilepsy, while better and more rapid results are obtained in monotherapy.
AB - Carbamazepine plasma levels were monitored for a twelve-month period in twenty epileptic patients. Seizure frequency decreased remarkably on inclusion of the drug in the therapy and attainment of plasma levels of 7-9 μg/ml. A faster breakdown rate in children was confirmed, while carbamazepine-10, 11-epoxide was present for carbamazepine levels above 4-5 μg/ml. EEG tracings did not show substantial modifications; this variable was thus considered to be of little value in assessing the clinical picture. Side-effects were minimal. Carbamazepine is increasingly becoming the drug of first choice in the management of both generalized and partial epilepsy, while better and more rapid results are obtained in monotherapy.
UR - http://www.scopus.com/inward/record.url?scp=0018352464&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018352464&partnerID=8YFLogxK
U2 - 10.1177/030006057900700207
DO - 10.1177/030006057900700207
M3 - Article
C2 - 478161
AN - SCOPUS:0018352464
VL - 7
SP - 152
EP - 157
JO - Journal of International Medical Research
JF - Journal of International Medical Research
SN - 0300-0605
IS - 2
ER -